Introduction Antiandrogens are candidates against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to host cell entry inhibition by the suppression of TMPRSS2. Proxalutamide is a nonsteroidal anti-androgen (NSAA) with strong antagonism on androgen receptor (AR) and angiotensin-converting enzyme 2 (ACE2). Efficacy of proxalutamide was previously demonstrated for early COVID-19 outpatients, and also reduction of deaths in hospitalized COVID-19 patients. Whether radiological changes would follow the improvement in clinical outcomes with proxalutamide is not established. The present post-hoc analysis aims to evaluate whether proxalutamide improves lung injury observed through chest computerized tomography (CT) scans.

中文翻译：

---

Proxalutamide 改善住院 COVID-19 患者的肺损伤——Proxa-Rescue AndroCoV 试验的放射学结果分析

引言抗雄激素是对抗严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 疾病 (COVID-19) 的候选药物，因为 TMPRSS2 的抑制抑制了宿主细胞进入。Proxalutamide 是一种非甾体类抗雄激素 (NSAA)，对雄激素受体 (AR) 和血管紧张素转换酶 2 (ACE2) 具有强拮抗作用。先前证明了普鲁胺对早期 COVID-19 门诊患者的疗效，以及减少住院 COVID-19 患者的死亡人数。尚未确定放射学变化是否会跟随普鲁胺临床结果的改善。本事后分析旨在评估普鲁胺是否能改善通过胸部计算机断层扫描 (CT) 扫描观察到的肺损伤。